Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to $65000.0.

  • Agios Pharmaceuticals' Gains from Investment Securities rose 29117.65% to $65000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 18083.57%. This contributed to the annual value of $39000.0 for FY2024, which is 10705.24% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Gains from Investment Securities is $65000.0, which was up 29117.65% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Gains from Investment Securities peaked at $6.1 million during Q2 2021, and registered a low of -$8.3 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $103315.8, with a median of $84000.0 in 2022.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Gains from Investment Securities showed a top increase of 700930.23% in 2021 and a maximum decrease of 979534.88% in 2021.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Gains from Investment Securities stood at -$8.3 million in 2021, then soared by 101.0% to $83000.0 in 2022, then plummeted by 2677.11% to -$2.1 million in 2023, then surged by 131.6% to $676000.0 in 2024, then tumbled by 90.38% to $65000.0 in 2025.
  • Its Gains from Investment Securities was $65000.0 in Q3 2025, compared to $1.3 million in Q2 2025 and $188000.0 in Q1 2025.